Pharmaceutica Analytica Acta

Medicines for Children: Overview, Future Needs, Problems and their Solutions

2^nd International Conference on Pharmaceutics & Novel Drug Delivery Systems

20-22 February 2012 San Francisco Airport Marriott Waterfront, USA

Alastair Sutcliffe

Accepted Abstracts: Pharm Anal Acta

Abstract:

We are moving away from children being perceived as the therapeutic orphan but only just. A brief overview of previous disasters where the child was perceived as a miniature adult, through a description of what are the rate limiting steps in drug delivery at the bed side will be followed, by identification of pressing therapeutic needs for colleagues involved in drug discovery and development. These will essentially follow the EMEA rather than the FDA model but will also touch on the issue of PPI (Public patient involvement) in considering future needs.

Biography :

Professor Sutcliffe has completed his MD and PhD at the age of 25 years from Manchester and subsequently University College London. His postdoctoral studies are mainly from University College London where he has been a senior member of staff since 1995. He is a clinician/staffer at University College London Hospitals and also Great Ormond Street Hospital for Sick Children. He is associate director of the London based branch of the national NIHR funded Medicines For Children Research Network. This is presently conducting 166 clinical trials in medicines for children in the London network responsive to 2 million children. He has published more than 100 papers in reputed journals and serving as an editorial board member of repute on the British National Formulary for Children.